Profile data is unavailable for this security.
About the company
e-Therapeutics Plc is a drug discovery platform company. It is engaged in developing a computational approach to drug discovery, leveraging network biology to capture and interrogate human disease complexity. Its biology-led silico laboratory enables hypothesis generation, phenotypic screening and the identification and prioritization of novel therapeutic targets. It has developed a proprietary GalNAc-siRNA platform technology for specific silencing of gene expression in the liver. Its computational platform includes HepNet, a hepatocyte-specific, computational biology platform that enables identification of target genes to unlock differentiated therapeutic development at scale. Its GalOmic platform is its proprietary ribonucleic acid (RNA) Interference (RNAi) chemistry platform. In combination with HepNet, it offers end-to-end capabilities for rapid identification of novel disease-associated genes and drug candidate development of therapies with disease-modifying potential.
- Revenue in GBP (TTM)475.00k
- Net income in GBP-8.27m
- Incorporated2001
- Employees38.00
- LocationE-Therapeutics PLCFloor 44 Kingdom Street, Paddington CentralLONDON W2 6BDUnited KingdomGBR
- Phone+44 204 551 8888
- Fax+44 199 388 0207
- Websitehttps://www.etherapeutics.co.uk/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Science in Sport PLC | 65.93m | -7.07m | 28.71m | 158.00 | -- | 0.7213 | -- | 0.4354 | -0.0464 | -0.0464 | 0.4239 | 0.2184 | 0.8479 | 4.20 | 3.83 | 417,278.50 | -9.09 | -9.69 | -13.75 | -11.97 | 41.88 | 47.09 | -10.72 | -11.94 | 0.6921 | -2.31 | 0.2825 | -- | 1.97 | 32.50 | -96.47 | -- | 49.81 | -- |
| CRUSHMETRIC Group Ltd | 397.92k | -878.53k | 29.94m | 20.00 | -- | 1.17 | -- | 75.23 | -0.0072 | -0.0072 | 0.0028 | 0.1061 | 0.0255 | 7.14 | 2.64 | 19,895.79 | -5.72 | -40.65 | -8.35 | -- | 34.66 | 37.39 | -224.56 | -140.54 | 0.072 | -14.42 | 0.0558 | -- | 119.19 | -1.40 | -7.26 | -- | 12.11 | -- |
| Redx Pharma PLC | 4.20m | -33.16m | 38.90m | 101.00 | -- | 9.98 | -- | 9.26 | -0.099 | -0.099 | 0.0126 | 0.01 | 0.0954 | -- | 135.55 | 41,603.96 | -75.26 | -52.99 | -166.19 | -88.10 | -- | -- | -789.05 | -206.66 | -- | -- | 0.8405 | -- | -77.52 | 100.71 | -84.15 | -- | 8.12 | -- |
| Arecor Therapeutics PLC | 3.38m | -9.42m | 41.81m | 51.00 | -- | 3.16 | -- | 12.37 | -0.3108 | -0.3108 | 0.1114 | 0.4314 | 0.1805 | -- | 0.7516 | 66,254.90 | -50.32 | -- | -66.40 | -- | -- | -- | -278.81 | -- | 2.28 | -- | 0.0125 | -- | 107.51 | -- | -50.11 | -- | -- | -- |
| Venture Life Group PLC | 51.41m | 921.00k | 53.45m | 165.00 | 79.27 | 0.7009 | 6.61 | 1.04 | 0.0053 | 0.0053 | 0.3847 | 0.6028 | 0.42 | 2.80 | 3.15 | 311,575.80 | 0.7525 | 1.58 | 0.9274 | 1.83 | 39.19 | 40.14 | 1.79 | 3.99 | 0.7355 | 2.12 | 0.2424 | 0.00 | 16.89 | 22.33 | 77.12 | 31.30 | 18.85 | -- |
| e-Therapeutics plc | 475.00k | -8.27m | 56.10m | 38.00 | -- | 1.69 | -- | 118.10 | -0.0154 | -0.0154 | 0.0009 | 0.0568 | 0.0148 | -- | 1.92 | 12,500.00 | -25.79 | -33.25 | -27.10 | -35.11 | 100.00 | 100.00 | -1,741.90 | -1,490.90 | -- | -- | 0.0089 | -- | -0.4193 | -- | -2.53 | -- | 24.22 | -- |
| Poolbeg Pharma PLC | 0.00 | -4.89m | 58.00m | 12.00 | -- | 3.50 | -- | -- | -0.0098 | -0.0098 | 0.00 | 0.0331 | 0.00 | -- | -- | 0.00 | -25.02 | -- | -25.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -100.60 | -- | -- | -- |
| Celadon Pharmaceuticals PLC | 20.74k | -8.06m | 67.42m | -- | -- | 21.51 | -- | 3,250.69 | -0.1306 | -0.1306 | 0.0003 | 0.0488 | 0.0016 | 267.85 | 0.0248 | -- | -64.68 | -- | -71.16 | -- | -29,080.42 | -- | -40,384.18 | -- | 1.84 | -12.45 | 0.6052 | -- | -- | -- | -- | -- | -- | -- |
| Eco Animal Health Group Plc | 88.46m | -1.62m | 69.44m | 228.00 | -- | 0.8515 | 28.81 | 0.785 | -0.024 | -0.024 | 1.31 | 1.20 | 0.7664 | 1.92 | 3.41 | 387,986.80 | -0.1949 | 6.03 | -0.2645 | 8.02 | 43.05 | 46.41 | -0.2544 | 7.89 | 2.26 | 1.22 | 0.0437 | 55.72 | 3.79 | 4.89 | 246.94 | -35.90 | -4.43 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Bank J. Safra Sarasin AG (Investment Management)as of 01 Apr 2024 | 25.30m | 4.33% |
| Schroder Investment Management Ltd.as of 01 Apr 2024 | 13.90m | 2.38% |
| Investec Wealth & Investment Ltd.as of 01 Apr 2024 | 8.20m | 1.40% |
| Fidelity Investments Canada ULCas of 01 Apr 2024 | 5.86m | 1.00% |
| IG Markets Ltd.as of 01 Apr 2024 | 5.01m | 0.86% |
| Cantor Fitzgerald Europeas of 01 Apr 2024 | 4.57m | 0.78% |
| Hargreaves Lansdown Asset Management Ltd.as of 01 Apr 2024 | 2.92m | 0.50% |
| Coutts & Co.as of 01 Apr 2024 | 2.76m | 0.47% |
| Rathbones Investment Management Ltd.as of 01 Apr 2024 | 1.86m | 0.32% |
| KW Investment Management Ltd.as of 01 Apr 2024 | 1.22m | 0.21% |
